GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Atlantic International Corp (NAS:ATLN) » Definitions » Net Cash per Share

ATLN (Atlantic International) Net Cash per Share : $-2.52 (As of Dec. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Atlantic International Net Cash per Share?

Net Cash per Share is calculated as Cash, Cash Equivalents, Marketable Securities minus Total Liabilities minus Minority Interest and then divided by Shares Outstanding (EOP). Atlantic International's Net Cash per Share for the quarter that ended in Dec. 2024 was $-2.52.

The historical rank and industry rank for Atlantic International's Net Cash per Share or its related term are showing as below:

During the past 8 years, the highest Price-to-Net-Cash Ratio of Atlantic International was 3.01. The lowest was 1.59. And the median was 2.30.

ATLN's Price-to-Net-Cash is not ranked *
in the Medical Diagnostics & Research industry.
Industry Median: 6.25
* Ranked among companies with meaningful Price-to-Net-Cash only.

Atlantic International Net Cash per Share Historical Data

The historical data trend for Atlantic International's Net Cash per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Atlantic International Net Cash per Share Chart

Atlantic International Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Net Cash per Share
Get a 7-Day Free Trial -15.58 24.88 7.31 -432.20 -2.52

Atlantic International Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Net Cash per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -432.20 -5.48 -2.52 -2.60 -2.52

Competitive Comparison of Atlantic International's Net Cash per Share

For the Diagnostics & Research subindustry, Atlantic International's Price-to-Net-Cash, along with its competitors' market caps and Price-to-Net-Cash data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Atlantic International's Price-to-Net-Cash Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Atlantic International's Price-to-Net-Cash distribution charts can be found below:

* The bar in red indicates where Atlantic International's Price-to-Net-Cash falls into.


;
;

Atlantic International Net Cash per Share Calculation

In the calculation of a company's Net Cash per Share, assets other than cash and short term investments are considered to be worth nothing. But the company has to pay its debt and other liabilities in full. This is an extremely conservative way of valuation. Most companies have negative Net Cash per Share. But sometimes a company's price may be lower than its net-cash.

Atlantic International's Net Cash per Share for the fiscal year that ended in Dec. 2024 is calculated as

Net Cash per Share (A: Dec. 2024 )
=(Cash, Cash Equivalents, Marketable Securities-Total Liabilities-Minority Interest)/Shares Outstanding (EOP)
=(0.679-134.768-0)/53.131
=-2.52

Atlantic International's Net Cash per Share for the quarter that ended in Dec. 2024 is calculated as

Net Cash per Share (Q: Dec. 2024 )
=(Cash, Cash Equivalents, Marketable Securities-Total Liabilities-Minority Interest)/Shares Outstanding (EOP)
=(0.679-134.768-0)/53.131
=-2.52

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Atlantic International  (NAS:ATLN) Net Cash per Share Explanation

Ben Graham invested in situations where the company's stock price was lower than its net-cash. He assigned some value to the company's other current asset. The value is called Net Current Asset Value (NCAV). One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Graham's strategy produced similar results.

You can find companies that are traded below their Net Current Asset Value (NCAV) with our Net-Net screener.


Atlantic International Net Cash per Share Related Terms

Thank you for viewing the detailed overview of Atlantic International's Net Cash per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Atlantic International Business Description

Traded in Other Exchanges
N/A
Address
3 Federal Street, Billerica, MA, USA, 01821
Atlantic International Corp formerly SeqLL Inc is a technology company providing life sciences instrumentation and research services in collaborative partnerships aimed at the development of novel scientific assets and intellectual property across multiple omics fields. The company leverages its expertise with the True Single Molecule Sequencing platform to empower scientists and researchers with improved genetic tools to greater understand the molecular mechanisms of disease that is essential to the continued development of new breakthroughs in genomic medicine, and that hopefully address the critical concerns involved with precision medicine.
Executives
Daniel Robert Jones officer: President, CEO 317 NEW BOSTON STREET, SUITE 210, WOBURN MA 01801
Douglas Patrick Miscoll director 317 NEW BOSTON STREET, SUITE 2010, WOBURN MA 01801
David Pfeffer director 464 IVY AVENUE, HAWORTH NJ 07644
Patrice M. Milos director 317 NEW BOSTON STREET, SUITE 2010, WOBURN MA 01801
Frances P Scally officer: CHIEF FINANCIAL OFFICER 66 MELANIE LANE, SYOSSET NY 11791
John Whitcomb Kennedy officer: CFO, Secretary 166 WINN STREET, WOBURN MA 01801